Dr. Jorge E. Cortes           CML       Chronic Myeloid Leukemia

''Jorge Cortes, MD, is deputy chair and professor of medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston Texas where he directs the CML Program.''

Extract from the site of iCMLf (International Chronic Myeloid Leukemia Foundation).

VIDEOS

Faster, Better, Safer—Getting CML Treatment Right
December 23, 2016, PeerView Oncology

Mutation Analysis in Chronic Myeloid Leukemia
January 14, 2016, OncLive

Study Brings Positive Results For the Most Resistant Types of CML
December 11, 2012,  Patient Power

An Expert Explains Positive News on CML VIDEO
June 27, 2012, Patient Power

Dr. Jorge Cortes Discusses the Ponatinib Ph+All and CML Evaluation (PACE) Trial
June 14, 2012, OncLive

Living with CML Long-Term: Side-Effects, Treatment Cessation and Better Testing
January 22, 2012,  Patient Power

Living With CML - Side Effects and Symptom Management              
January 11, 2012, Patient Power

A Closer Watch and Newer Options for Better Long-Term Results   
December 29, 2011,  Patient Power

New Help for More CML Patients: Dr. Jorge Cortes
December 20, 2010, Patient Power

Treatment of patients after first line therapy 
December 2010, iCMLf

ASH2010 - The ponatinib, a molecule with many potential patients resistant
December 6, 2010, Médecine Plus

CML: The Current Landscape - an interview with Dr. Jorge Cortes 
October 2010, The National CML Society (US)

ASCO 2010: New treatments for CML (bosutinib)
September 2010, cancerconnect

CML Treatment: Old Drug, New Name                                                                           
December 18, 2009, ElsGlobalMedicalNews

Interview with Jorges Cortes at EHA "How long to leave patients on treatment?"
June 2008, EHA (European Hematology Association)

               

ARTICLES

FDA Approves Bosutinib for Newly-Diagnosed Ph+ CML
December 19, 2017,  OncLive

How I treat newly diagnosed chronic phase CML
August 16, 2012, Journal Blood